Teddy Kosoglou

Summary

Publications

  1. ncbi Effects of ezetimibe on the pharmacodynamics and pharmacokinetics of lovastatin
    Teddy Kosoglou
    Department of Early Clinical Research and Experimental Medicine, Schering Plough Research Institute, Kenilworth, NJ 07033 1300, USA
    Curr Med Res Opin 20:955-65. 2004
  2. pmc Pharmacodynamic interaction between the new selective cholesterol absorption inhibitor ezetimibe and simvastatin
    Teddy Kosoglou
    Schering Plough Research Institute, Kenilworth, NJ
    Br J Clin Pharmacol 54:309-19. 2002
  3. ncbi Pharmacokinetic interaction between ezetimibe and lovastatin in healthy volunteers
    Larisa Reyderman
    Department of Drug Metabolism and Pharmacokinetics, Schering Plough Research Institute, Kenilworth, NJ 07033 1300, USA
    Curr Med Res Opin 20:1493-500. 2004
  4. ncbi Pharmacodynamic and pharmacokinetic interaction between fenofibrate and ezetimibe
    Teddy Kosoglou
    Department of Early Clinical Research and Experimental Medicine, Schering Plough Research Institute, Kenilworth, NJ 07033, USA
    Curr Med Res Opin 20:1197-207. 2004
  5. ncbi Pharmacodynamic interaction between ezetimibe and rosuvastatin
    Teddy Kosoglou
    Department of Early Clinical Research and Experimental Medicine, Schering Plough Research Institute, Kenilworth, NJ 07033, USA
    Curr Med Res Opin 20:1185-95. 2004
  6. ncbi The effect of fluvastatin on the pharmacokinetics and pharmacodynamics of ezetimibe
    Larisa Reyderman
    Drug Metabolism and Pharmacokinetics, Schering Plough Research Institute, Kenilworth, NJ 07033 1300, USA
    Curr Med Res Opin 21:1171-9. 2005
  7. ncbi Ezetimibe: a review of its metabolism, pharmacokinetics and drug interactions
    Teddy Kosoglou
    Department of Early Clinical Research and Experimental Medicine, Schering Plough Research Institute, Kenilworth, New Jersey, USA
    Clin Pharmacokinet 44:467-94. 2005
  8. ncbi Disposition of the selective cholesterol absorption inhibitor ezetimibe in healthy male subjects
    James E Patrick
    Schering Plough Research Institute, Kenilworth, New Jersey 07033 1300, USA
    Drug Metab Dispos 30:430-7. 2002
  9. doi Once-daily evening dosing of mometasone furoate administered via a dry powder inhaler does not adversely affect the hypothalamic-pituitary-adrenal axis
    Teddy Kosoglou
    Early Clinical Research and Experimental Medicine, Schering Plough Research Institute, 2015 Galloping Hill Road K 15 4, 4455, Kenilworth, NJ 07033, USA
    Chest 137:115-21. 2010
  10. ncbi Effects of ezetimibe on cyclosporine pharmacokinetics in healthy subjects
    Arthur J Bergman
    Merck Research Laboratories, West Point, PA 19486, USA
    J Clin Pharmacol 46:321-7. 2006

Collaborators

  • Bo Yang
  • Larisa Reyderman
  • Jean Charles Fruchart
  • Arthur J Bergman
  • Paul Statkevich
  • Patrick Larson
  • Amy O Johnson-Levonas
  • Keith Gottesdiener
  • John F Paolini
  • Gail Murphy
  • Joanne Burke
  • Stephen E Maxwell
  • James E Patrick
  • Howard E Greenberg
  • Glenn Frick
  • Richard Robson
  • Walter K Kraft
  • Kathe L Stauber
  • Mitchell N Cayen
  • Yali Zhu
  • Melton Affrime
  • Robert Iannucci
  • Swapan Chowdhury
  • Kevin B Alton

Detail Information

Publications11

  1. ncbi Effects of ezetimibe on the pharmacodynamics and pharmacokinetics of lovastatin
    Teddy Kosoglou
    Department of Early Clinical Research and Experimental Medicine, Schering Plough Research Institute, Kenilworth, NJ 07033 1300, USA
    Curr Med Res Opin 20:955-65. 2004
    ..This study investigated the potential for pharmacodynamic and/or pharmacokinetic interactions between ezetimibe and lovastatin...
  2. pmc Pharmacodynamic interaction between the new selective cholesterol absorption inhibitor ezetimibe and simvastatin
    Teddy Kosoglou
    Schering Plough Research Institute, Kenilworth, NJ
    Br J Clin Pharmacol 54:309-19. 2002
    ..Evaluation of the tolerance of the coadministration of ezetimibe and simvastatin was a secondary objective...
  3. ncbi Pharmacokinetic interaction between ezetimibe and lovastatin in healthy volunteers
    Larisa Reyderman
    Department of Drug Metabolism and Pharmacokinetics, Schering Plough Research Institute, Kenilworth, NJ 07033 1300, USA
    Curr Med Res Opin 20:1493-500. 2004
    ..The current study was designed to further investigate the potential for pharmacokinetic interaction between ezetimibe and lovastatin...
  4. ncbi Pharmacodynamic and pharmacokinetic interaction between fenofibrate and ezetimibe
    Teddy Kosoglou
    Department of Early Clinical Research and Experimental Medicine, Schering Plough Research Institute, Kenilworth, NJ 07033, USA
    Curr Med Res Opin 20:1197-207. 2004
    ..The pharmacodynamic, pharmacokinetic, and safety profiles of ezetimibe and fenofibrate were evaluated alone and after co-administration in 32 subjects with primary hypercholesterolemia...
  5. ncbi Pharmacodynamic interaction between ezetimibe and rosuvastatin
    Teddy Kosoglou
    Department of Early Clinical Research and Experimental Medicine, Schering Plough Research Institute, Kenilworth, NJ 07033, USA
    Curr Med Res Opin 20:1185-95. 2004
    ..A secondary objective was to examine the potential for a pharmacokinetic interaction between ezetimibe and rosuvastatin...
  6. ncbi The effect of fluvastatin on the pharmacokinetics and pharmacodynamics of ezetimibe
    Larisa Reyderman
    Drug Metabolism and Pharmacokinetics, Schering Plough Research Institute, Kenilworth, NJ 07033 1300, USA
    Curr Med Res Opin 21:1171-9. 2005
    ....
  7. ncbi Ezetimibe: a review of its metabolism, pharmacokinetics and drug interactions
    Teddy Kosoglou
    Department of Early Clinical Research and Experimental Medicine, Schering Plough Research Institute, Kenilworth, New Jersey, USA
    Clin Pharmacokinet 44:467-94. 2005
    ..Because treatment experience in patients receiving ciclosporin is limited, physicians are advised to exercise caution when initiating ezetimibe in the setting of ciclosporin coadministration, and to carefully monitor ciclosporin levels...
  8. ncbi Disposition of the selective cholesterol absorption inhibitor ezetimibe in healthy male subjects
    James E Patrick
    Schering Plough Research Institute, Kenilworth, New Jersey 07033 1300, USA
    Drug Metab Dispos 30:430-7. 2002
    ..The pharmacokinetics of ezetimibe are consistent with extensive glucuronidation and enterohepatic recirculation. The primary metabolic pathway for ezetimibe is by glucuronidation of the 4-hydroxyphenyl group...
  9. doi Once-daily evening dosing of mometasone furoate administered via a dry powder inhaler does not adversely affect the hypothalamic-pituitary-adrenal axis
    Teddy Kosoglou
    Early Clinical Research and Experimental Medicine, Schering Plough Research Institute, 2015 Galloping Hill Road K 15 4, 4455, Kenilworth, NJ 07033, USA
    Chest 137:115-21. 2010
    ..This study reports the effects of moderate-dose (400 microg) mometasone furoate administered via dry powder inhaler (MF-DPI) once daily in the evening on the HPA axis in adults with mild to moderate asthma...
  10. ncbi Effects of ezetimibe on cyclosporine pharmacokinetics in healthy subjects
    Arthur J Bergman
    Merck Research Laboratories, West Point, PA 19486, USA
    J Clin Pharmacol 46:321-7. 2006
    ..CyA concentrations should be monitored in patients receiving EZE and CyA...
  11. ncbi Interaction of single-dose ezetimibe and steady-state cyclosporine in renal transplant patients
    Arthur J Bergman
    Clinical Drug Metabolism, Merck Research Laboratories, WP 75 100, Sumneytown Pike, PO Box 4, West Point, PA 19486, USA
    J Clin Pharmacol 46:328-36. 2006
    ..Because the long-term safety implications of both higher EZE exposures and undetermined effect on CyA are not yet understood, the clinical significance of this interaction is unknown...